Lamotrigine as Treatment of Myotonia

Key facts

Sponsor

Grete Andersen, MD

Principal Investigator

Grete Andersen, MD

Copenhagen Neuromuscular Center, Rigshospitalet, Denmark, Europe

Intervention

Lamotrigine(drug)

Enrollment

27 enrolled

Eligibility

18 years · All sexes

Timeline

2013 – 2015

Study locations (1)

• Copenhagen Neuromuscular Center, department of Neurology, Rigshospitalet, Copenhagen, Denmark

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Thomsen and Becker disease

Additional recruiting or active studies for the same condition.

• ENROLLING BY INVITATIONPHASE3NCT07008469
  Global Open-Label Extension Study of Del-desiran for the Treatment of DM1
  Avidity Biosciences, Inc.
• ACTIVE NOT RECRUITINGPHASE3NCT06411288
  Global Study of Del-desiran for the Treatment of DM1
  Avidity Biosciences, Inc.

See all trials for Thomsen and Becker disease →